Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Suyash M. Patil"'
Publikováno v:
Pharmaceuticals, Vol 17, Iss 6, p 754 (2024)
Tuberculosis (TB) is an airborne bacterial infection caused by Mycobacterium tuberculosis (M. tb), resulting in approximately 1.3 million deaths in 2022 worldwide. Oral therapy with anti-TB drugs often fails to achieve therapeutic concentrations at t
Externí odkaz:
https://doaj.org/article/eea400d0b05045f19e7d34d2eac35317
Autor:
Kailash C. Petkar, Suyash M. Patil, Sandip S. Chavhan, Kan Kaneko, Krutika K. Sawant, Nitesh K. Kunda, Imran Y. Saleem
Publikováno v:
Pharmaceutics, Vol 13, Iss 4, p 455 (2021)
The development of vaccines is one of the most significant medical accomplishments which has helped to eradicate a large number of diseases. It has undergone an evolutionary process from live attenuated pathogen vaccine to killed whole organisms or i
Externí odkaz:
https://doaj.org/article/8a495aaa7406414f8d3919af7c2c3fc5
Publikováno v:
International Journal of Molecular Sciences, Vol 21, Iss 20, p 7575 (2020)
Conventional anti-cancer therapy involves the use of chemical chemotherapeutics and radiation and are often non-specific in action. The development of drug resistance and the inability of the drug to penetrate the tumor cells has been a major pitfall
Externí odkaz:
https://doaj.org/article/5c6e43cd38fd48548233bd445ebbda27
Autor:
Suyash M. Patil, Druva Sarika Barji, Tejashri Chavan, Kinjal Patel, Andrew J. Collazo, Vasudha Prithipaul, Aaron Muth, Nitesh K. Kunda
Publikováno v:
AAPS PharmSciTech. 24
Autor:
Suyash M. Patil, Snehal K. Shukla, Shruti S. Sawant, Nishant S. Kulkarni, Nitesh K. Kunda, Vivek Gupta
Publikováno v:
Drug Delivery and Translational Research. 12:2474-2487
Osimertinib (OB) is a third-generation irreversible tyrosine kinase inhibitor targeting the epidermal growth factor receptor (EGFR), overexpressed in non-small cell lung cancer. Systemic administration of drug often results in poor drug levels at the
Autor:
Suyash M. Patil, Druva Sarika Barji, Sophia Aziz, David A. McChesney, Shapali Bagde, Pavan Muttil, Nitesh K. Kunda
Publikováno v:
International Journal of Pharmaceutics. 634:122641
Autor:
Suyash M. Patil, Nitesh K. Kunda
Publikováno v:
Biochimie. 201
Non-small cell lung cancer (NSCLC) is a major cause of global cancer mortalities and accounts for approximately 80-85% of reported lung cancer cases. Conventional chemotherapeutics show limited application because of poor tumor selectivity and acquir
Autor:
Richa Vartak, Nitesh K. Kunda, Ketan Patel, Manali Patki, Aishwarya Saraswat, Suyash M. Patil
Publikováno v:
Nanomedicine
Aim: To formulate an aerosolized nanoliposomal carrier for remdesivir (AL-Rem) against coronavirus disease 2019. Methods: AL-Rem was prepared using modified hydration technique. Cytotoxicity in lung adenocarcinoma cells, stability and aerodynamic cha
Publikováno v:
International Journal of Molecular Sciences, Vol 21, Iss 7575, p 7575 (2020)
International Journal of Molecular Sciences
International Journal of Molecular Sciences
Conventional anti-cancer therapy involves the use of chemical chemotherapeutics and radiation and are often non-specific in action. The development of drug resistance and the inability of the drug to penetrate the tumor cells has been a major pitfall
Publikováno v:
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V. 154
Exosomes are intracellular membrane-based vesicles with diverse compositions that are involved in biological and pathological processes. Since the discovery of exosomes, they have been used as diagnostic biomarkers and as potential drug delivery vehi